A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 523-523 ◽  
Author(s):  
Anabel Beatriz Sanchez-Spitman ◽  
Vincent O. Dezentjé ◽  
Jesse J Swen ◽  
Dirk Jan A.R. Moes ◽  
Erdogan Batman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Prospective Study ◽  
Cancer Patients ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Adjuvant Tamoxifen ◽  
Breast Cancer Patients ◽  
A Prospective Study ◽  
Endoxifen Concentration

Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study

2009 ◽  
Vol 18 (8) ◽  
pp. 811-821 ◽  
Author(s):  
Barbara Collins ◽  
Joyce Mackenzie ◽  
Angela Stewart ◽  
Catherine Bielajew ◽  
Shailendra Verma
Keyword(s):  
Breast Cancer ◽  
Prospective Study ◽  
Cancer Patients ◽  
Hormonal Therapy ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Cognitive Effects ◽  
Breast Cancer Patients ◽  
A Prospective Study

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

1996 ◽  
Vol 14 (10) ◽  
pp. 2702-2708 ◽  
Author(s):  
C Carlomagno ◽  
F Perrone ◽  
C Gallo ◽  
M De Laurentiis ◽  
R Lauria ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Early Stage ◽  
Cox Model ◽  
Early Stage Breast Cancer ◽  
Adjuvant Tamoxifen ◽  
Independent Effect ◽  
Axillary Lymph ◽  
Breast Cancer Patients

PURPOSE We studied retrospectively the interaction between c-erbB2 overexpression and adjuvant tomoxifen in node-negative breast cancer patients enrolled in the Gruppo Universitario Napoletano 1 (GUN-1) trial. PATIENTS AND METHODS c-erbB2, evaluated by immunohistochemistry in 145 of 173 patients randomly assigned to 2-year adjuvant tamoxifen or no further therapy, was considered overexpressed if greater than 10% of the cells showed specific membrane staining. The role of each prognostic variable and their independent effect were studied using the Cox model. Disease-free (DFS) and overall (OAS) survival curves were estimated by the Kaplan-Meier method. RESULTS As of November 30, 1994, the median follow-up period was 12 years. c-erbB2 was overexpressed in 43 of 145 patients (29.7%), which directly correlated with tumor size and inversely with estrogen receptor (ER) level. At univariate analysis, overexpression of c-erbB2 did not affect either DFS or OAS; tamoxifen had a greater effect on reducing the risk of recurrence than of death. Addition of c-erbB2 to a multivariate Cox model that contained menopausal status, tumor size, nuclear grade, and treatment as covariates did not affect the significance of the model for DSF or OAS, whereas addition of the first-order interaction between c-erbB2 and tamoxifen was statistically significant both for DFS and OAS. The same result was obtained when the model contained ER status and ER-tamoxifen interaction. Indeed, adjuvant tamoxifen significantly prolonged DFS and OAS in c-erbB2-negative cases, whereas it had no effect on DFS and OAS in c-erbB2-positive patients. CONCLUSION In early-stage breast cancer patients, overexpression of c-erbB2 is a marker of lack of efficacy of adjuvant tamoxifen.

A prospective study on behavioral symptoms’ impact to the quality of life in patients with early-stage cancer receiving radiotherapy.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 46-46
Author(s):  
Canhua Xiao ◽  
Jennifer Felger ◽  
Donna Mister ◽  
Tian Liu ◽  
Andrew H. Miller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Prospective Study ◽  
Cancer Patients ◽  
Early Stage ◽  
Behavioral Symptoms ◽  
Breast Cancer Patients ◽  
A Prospective Study ◽  
Over Time

46 Background: Fatigue, sleep problems, and depression are the most common behavioral symptoms experienced by breast cancer patients. The purpose of this study was to examine these behavioral symptoms’ impact on quality of life (QOL) for early stage breast cancer patients receiving radiotherapy (RT). Methods: This was a prospective study of 46 patients receiving whole breast RT (50 Gy plus a 10 Gy boost) following lumpectomy. Data were collected at pre-RT, week 6 of RT, and 6-weeks post-RT. QOL was measured by Short Form-36, fatigue by Multidimensional Fatigue Inventory, sleep by Pittsburgh Sleep Quality Index, depression by Inventory for Depressive Symptomatology-Self-Rated, and stress by Perceived Stress Scale. No patients were treated with chemotherapy. Demographic/clinical variables, including age, race, marriage, smoking history, hormone treatment, and cancer stage, were collected at the time of enrollment. Mixed effect modeling was utilized to observe behavioral symptoms’ impact on QOL over time. Results: Fatigue and depression, along with stress, had significant impact on QOL after controlling for body mass index (BMI; the only one significant demographic/clinical variable; see Table). Patients with more fatigue, depression, or stress were more likely to have worse QOL during and post-RT. Patients having a higher BMI at baseline also reported worse QOL over time. Sleep was significantly correlated with QOL in univariate analyses, while this effect disappeared in multivariate models. Conclusions: Behavioral symptoms, in particular fatigue and depression, along with stress, have significant impact on the QOL of early breast cancer patients’ receiving RT. Future research on the underlying biological mechanisms will improve our understanding of these symptoms and their relationships, which will help to find potential targets for multiple related symptoms and, ultimately, improve patients’ QOL. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document